Stomach cancer laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(One intermediate revision by one other user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{MAD}}
{{CMG}}; {{AE}} {{MAD}}
==Overview==
==Overview==
Laboratory findings in gastric cancer include [[anemia]] of chronic disease on [[complete blood count]], [[liver function tests]] may reveal abnormalities in [[liver function tests]], antigens such as [[carcinoembryonic antigen]], [[CA-125|glycoprotein CA 125]], [[CA19-9|carbohydrate antigen 19-9]], cancer antigen 72-4, [[alpha-fetoprotein]].  
[[Laboratory]] findings in [[gastric cancer]] include [[anemia]] of [[chronic disease]] on [[complete blood count]], [[liver function tests]] may reveal [[abnormalities]] in [[liver function tests]], [[antigens]] such as [[carcinoembryonic antigen]], [[CA-125|glycoprotein CA 125]], [[CA19-9|carbohydrate antigen 19-9]], [[cancer]] [[antigen]] 72-4, [[alpha-fetoprotein]].  


== Stomach cancer laboratory findings ==
== Stomach cancer laboratory findings ==
* A [[Complete blood count|complete blood cell count]] shows [[anemia]] of chronic disease.
* A [[Complete blood count|complete blood cell count]] shows [[anemia]] of [[chronic disease]].


* [[Liver function tests]] may be disturbed in patients with [[liver]] [[metastasis]].
* [[Liver function tests]] may be disturbed in [[patients]] with [[liver]] [[metastasis]].


* [[Carcinoembryonic antigen]] ([[CEA]]) is elevated in 50% of patients. A drop in an elevated level of [[CEA]] means response to preoperative therapy but it is not ''sensitive'' or specific.
* [[Carcinoembryonic antigen]] ([[CEA]]) is elevated in 50% of [[patients]]. A drop in an elevated level of [[CEA]] means response to preoperative [[therapy]] but it is not sensitive or specific.


* [[CA-125|Glycoprotein CA 125]] antigen may be elevated.<ref name="pmid280023202">{{cite journal| author=Luo T, Chen W, Wang L, Zhao H| title=CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study. | journal=Medicine (Baltimore) | year= 2016 | volume= 95 | issue= 51 | pages= e5297 | pmid=28002320 | doi=10.1097/MD.0000000000005297 | pmc=5181804 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28002320  }}</ref>   
* [[CA-125|Glycoprotein CA 125]] antigen may be elevated.<ref name="pmid280023202">{{cite journal| author=Luo T, Chen W, Wang L, Zhao H| title=CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study. | journal=Medicine (Baltimore) | year= 2016 | volume= 95 | issue= 51 | pages= e5297 | pmid=28002320 | doi=10.1097/MD.0000000000005297 | pmc=5181804 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28002320  }}</ref>   
* [[CA19-9|Carbohydrate antigen 19-9]] ([[CA 19-9]]) is elevated.<ref name="pmid18821070">{{cite journal| author=Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M| title=Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. | journal=Adv Ther | year= 2008 | volume= 25 | issue= 10 | pages= 1075-84 | pmid=18821070 | doi=10.1007/s12325-008-0100-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18821070  }}</ref>  
* [[CA19-9|Carbohydrate antigen 19-9]] ([[CA 19-9]]) is elevated.<ref name="pmid18821070">{{cite journal| author=Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M| title=Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. | journal=Adv Ther | year= 2008 | volume= 25 | issue= 10 | pages= 1075-84 | pmid=18821070 | doi=10.1007/s12325-008-0100-4 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18821070  }}</ref>  
* Cancer antigen 72-4 (CA72-4) may be elevated.<ref name="pmid7874576">{{cite journal| author=Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F et al.| title=CA 72-4 serum marker--a new tool in the management of carcinoma patients. | journal=Cancer Invest | year= 1995 | volume= 13 | issue= 2 | pages= 227-38 | pmid=7874576 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7874576  }}</ref>  
* [[Cancer]] [[antigen]] 72-4 (CA72-4) may be elevated.<ref name="pmid7874576">{{cite journal| author=Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F et al.| title=CA 72-4 serum marker--a new tool in the management of carcinoma patients. | journal=Cancer Invest | year= 1995 | volume= 13 | issue= 2 | pages= 227-38 | pmid=7874576 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7874576  }}</ref>  
* [[Alpha-fetoprotein]] ([[Alpha-fetoprotein|AFP]]) may be elevated.<ref name="pmid12435906">{{cite journal| author=Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H et al.| title=Clinicopathologic features of gastric cancers producing alpha-fetoprotein. | journal=Dig Surg | year= 2002 | volume= 19 | issue= 5 | pages= 359-65; discussion 365 | pmid=12435906 | doi=10.1159/000065838 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12435906  }}</ref>  
* [[Alpha-fetoprotein]] ([[Alpha-fetoprotein|AFP]]) may be elevated.<ref name="pmid12435906">{{cite journal| author=Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H et al.| title=Clinicopathologic features of gastric cancers producing alpha-fetoprotein. | journal=Dig Surg | year= 2002 | volume= 19 | issue= 5 | pages= 359-65; discussion 365 | pmid=12435906 | doi=10.1159/000065838 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12435906  }}</ref>  


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WS}}


[[Category:Needs content]]
[[Category:Needs content]]
Line 24: Line 27:
[[Category:Types of cancer]]
[[Category:Types of cancer]]
[[Category:Conditions diagnosed by stool test]]
[[Category:Conditions diagnosed by stool test]]
[[Category:Primary care]]
[[Category:Up-To-Date]]
 
{{WH}}
{{WS}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Surgery]]
[[Category:Surgery]]

Latest revision as of 00:18, 30 July 2020

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer laboratory findings

CDC on Stomach cancer laboratory findings

Stomach cancer laboratory findings in the news

Blogs on Stomach cancer laboratory findings

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Laboratory findings in gastric cancer include anemia of chronic disease on complete blood count, liver function tests may reveal abnormalities in liver function tests, antigens such as carcinoembryonic antigen, glycoprotein CA 125, carbohydrate antigen 19-9, cancer antigen 72-4, alpha-fetoprotein.

Stomach cancer laboratory findings

References

  1. Luo T, Chen W, Wang L, Zhao H (2016). "CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study". Medicine (Baltimore). 95 (51): e5297. doi:10.1097/MD.0000000000005297. PMC 5181804. PMID 28002320.
  2. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M (2008). "Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer". Adv Ther. 25 (10): 1075–84. doi:10.1007/s12325-008-0100-4. PMID 18821070.
  3. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F; et al. (1995). "CA 72-4 serum marker--a new tool in the management of carcinoma patients". Cancer Invest. 13 (2): 227–38. PMID 7874576.
  4. Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H; et al. (2002). "Clinicopathologic features of gastric cancers producing alpha-fetoprotein". Dig Surg. 19 (5): 359–65, discussion 365. doi:10.1159/000065838. PMID 12435906.

Template:WH Template:WS